Alan Cooke serves as chief executive officer, president and member of the board of directors. Prior to Sebela Pharmaceuticals, Alan held a number of executive-level positions primarily in pharmaceuticals and medical devices, including chief financial officer and subsequently chief executive officer of Trulife Group Limited; chief financial officer and subsequently president and chief operating officer of Amarin Corporation, plc; and vice president, global strategic planning of Elan Corporation, plc.
Alan is a fellow of the Institute of Chartered Accountants (Ireland), having qualified with KPMG in 1994. Alan also served as chairman of the board of the Institute of Neuroscience at Trinity College Dublin and is a Director of DS Biopharma Limited.
Paraic McDonogh serves as chief financial officer. Prior to Sebela Pharmaceuticals, Paraic was the global finance director and chief financial officer for Global Consolidated Aesthetics. Paraic has also held senior-level finance positions at Wellman International and KPMG.
Paraic is a fellow of the Institute of Chartered Accountants in Ireland and is a graduate of the National University of Ireland Galway.
Robert Raleigh serves as the chief operating officer and general counsel for Sebela Pharmaceuticals. Prior to working with Sebela Pharmaceuticals, Rob was the general counsel and director of purchasing and planning at Braintree Laboratories, Inc. from 2004 until 2018. From 1991 until 2004, Rob held a wide range of positions with Braintree Laboratories in operations, sales and business development. While at Braintree Laboratories, he also helped launch multiple products, managed the company’s supply chain, directed the intellectual property portfolio, and managed the company’s litigation. Rob has also advised multiple startup companies in the areas of diagnostics and pharmaceutical development.
Rob obtained his law degree as well as an MBA from Suffolk University in Boston, MA. Robert holds a BA in Economics from Stonehill College in Easton, MA.
SUE HALL, PhD
Dr. Sue Hall serves as head of research and development, women’s health and dermatology. Sue has over 30 years of international experience in pharmaceutical research and development. Prior to Sebela Pharmaceuticals, Sue served as executive vice president, chief scientific officer and global head of research and development for Endo Pharmaceuticals. There, she was responsible for the research and development pipeline and life cycle management for the marketed products portfolio of medicines and for the company’s quality assurance activities. Previously, Sue also served as senior vice president and global head of research and development for Valeant Pharmaceuticals. Sue also held several research and development leadership positions at GlaxoSmithKline, including clinical pharmacology, project management, medical affairs, and regulatory affairs.
Sue holds a PhD in Pharmacokinetics from the University of Manchester, UK, and a BS in Pharmacology from the University of Leeds, UK.
Scott Briggs serves as chief commercial officer. Scott has over 20 years of experience in pharmaceutical marketing and sales, strategic planning and business management. Prior to Sebela Pharmaceuticals, Scott served as vice president, marketing and sales at Noven Pharmaceuticals, where he led commercial operations. Previously, he also served Noven in the roles of vice president – women’s health sales, and executive director – marketing and managed markets. Prior to joining Noven, Scott was senior director of marketing for JDS Pharmaceuticals. He also has held leadership positions in management and marketing with Ortho-McNeil Pharmaceutical (part of Johnson & Johnson).
Scott holds a BA in Business Administration from Villanova University.
Tim Cavicchi serves as vice president of sales – gastroenterology. He has over 20 years of experience in pharmaceutical sales, marketing and training. Prior to Sebela Pharmaceuticals, Tim held a wide range of positions with Braintree Laboratories from 1995 to 2018, including territory manager, field sales trainer, regional sales manager, corporate training manager, director of sales and vice president of sales. While at Braintree Laboratories, he also helped launch and manage multiple products in the gastroenterology and renal therapeutic areas.
Tim is an adjunct professor in the marketing department at the Meehan School of Business – Stonehill College in Easton, MA and holds a BS in Business Administration from the University of Hartford and an MBA from Suffolk University.
Stuart Sedlack serves as vice president, business development. He has over 20 years of experience in the pharmaceutical industry, leading corporate business development and closing numerous transactions. Prior to joining Sebela Pharmaceuticals, Stuart was senior vice president, corporate development at Velocity Pharmaceutical Development, Amarin Pharma and Alba Therapeutics, serving as a member of the executive team at each company. Stuart also headed transaction negotiations for Novartis Pharma’s infectious disease franchise and served as vice president, corporate development at Elan Corporation after serving as director at the University of Maryland Medical System’s tech transfer office. Before entering the pharma industry, Stuart spent 5 years in international trade banking.
Stuart holds a BS in Economics from the University of Richmond and an MBA from Babson College.
Jai Wall serves as vice president, corporate affairs. Prior to joining Sebela Pharmaceuticals, Jai served as director of marketing and pediatric/dermatology sales at Arbor Pharmaceuticals Inc. He also held the position of vice president, commercial operations at Meda Pharmaceuticals US after its acquisition of Alaven Pharmaceuticals, where he ran the marketing department. Prior to Alaven, Jai held a number of positions with Solvay, both in the United States and in its corporate headquarters in Belgium, at Abbott Laboratories, and was one of the first employees at ZS Associates.
Jai holds a BS in Industrial Engineering With Distinction from Northwestern University and an MBA from Duke University.